NDAIMPLANTATIONIMPLANT
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
XARACOLL (bupivacaine hydrochloride) by Pfizer is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 2020.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XARACOLL is a bupivacaine hydrochloride implant approved by the FDA in August 2020 for local anesthesia via implantation. It works by blocking nerve impulses through increased electrical excitation threshold and slowed propagation of nerve impulses. The product is indicated for patients requiring sustained local anesthetic delivery at a surgical or procedural site.
Peak6.6 years to LOE
XARACOLL is in peak lifecycle stage with Pfizer's backing, suggesting stable commercial operations and mature go-to-market execution.
Mechanism of Action
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
XARACOLL offers career opportunities in a mature, Pfizer-backed product with strong patent protection and no direct competition. Roles will focus on commercial execution, market penetration, and maintaining market share through the peak lifecycle stage.
Brand Manager
Worked on XARACOLL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.